Three Advantages That BB Biotech Brings Us in the Traderfox Model Portfolio!

We see the biotechnology sector as a future winner in AI. The use of AI helps to shorten preclinical testing phases from 4 to 5 years down to 12 to 18 months, allowing for the design of safer molecules, which reduces failure rates. At the same time, AI will ensure that previously deadly diseases like cancer can be conquered much more easily. We expect AI-driven innovation growth, coupled with increased M&A activity, to lead to a boom in the biotech sector. In our model portfolios, we have initiated positions: BB Biotech is in the Germany portfolio,...